Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
Human dosing of LUNAR-COV19 expected soonDifferentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low dosesNew […]